Dr. Allan Kaplan, MSc, MD, FRCPC
Vice Dean, Senior Clinician Scientist, Chief of Research
Vice-Dean, Graduate & Life Sciences Education, Faculty of Medicine, University of Toronto, Senior Clinician/Scientist; Chief of Research, Centre for Addiction and Mental Health Professor, Department of Psychiatry, University of Toronto
Dr. Kaplan has focused his research on the psychobiology of anorexia nervosa (AN) and bulimia nervosa (BN). This has included research on the medical complications of AN and BN as well as the neuroendocrinology of these disorders, including neurotransmitter abnormalities in both the serotonergic and dopaminergic systems in BN and AN. Dr. Kaplan has also developed and rigorously evaluated innovative treatments such as day hospitalization and community- based treatments for eating disorders, and examined predictors of outcome in AN and BN. He has also conducted randomized controlled trials evaluating relapse prevention strategies for AN utilizing cognitive behaviour therapy and fluoxetine. More recently Dr. Kaplan has focused on innovative pharmacologic approaches to anorexia nervosa and on the genetics of anorexia and bulimia nervosa. This includes conducting research as part of a large multi-site consortium evaluating the genetics of AN and BN utilizing linkage analyses, candidate gene analyses and genome wide association studies. In collaboration with other investigators at CAMH, Dr. Kaplan’s research has examined genetic factors in weight regulation and caloric intake in obese and non-obese binge eaters.